Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 1:47 AM
Ignite Modification Date: 2025-12-26 @ 12:06 AM
NCT ID: NCT00031694
Description: None
Frequency Threshold: 5
Time Frame: None
Study: NCT00031694
Study Brief: Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Treatment (Paclitaxel, Bryostatin 1) Patients receive paclitaxel IV over 1 hour on day 1 followed by bryostatin 1 IV over 1 hour on day 2 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. paclitaxel: Given IV bryostatin 1: Given IV pharmacological study: Correlative studies None None 10 19 7 19 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Leukopenia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (2.0) View
Anemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (2.0) View
Death SYSTEMATIC_ASSESSMENT General disorders CTCAE (2.0) View
Abdominal pain SYSTEMATIC_ASSESSMENT General disorders CTCAE (2.0) View
Infection SYSTEMATIC_ASSESSMENT Infections and infestations CTCAE (2.0) View
Myalgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders CTCAE (2.0) View
Thrombosis/embolism SYSTEMATIC_ASSESSMENT Vascular disorders CTCAE (2.0) View
Hemorrhage SYSTEMATIC_ASSESSMENT Vascular disorders CTCAE (2.0) View
ALT/SGPT SYSTEMATIC_ASSESSMENT Hepatobiliary disorders CTCAE (2.0) View
AST/SGOT SYSTEMATIC_ASSESSMENT Hepatobiliary disorders CTCAE (2.0) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Leukopenia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (2.0) View
Anemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (2.0) View
Myalgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders CTCAE (2.0) View
Abdominal pain SYSTEMATIC_ASSESSMENT General disorders CTCAE (2.0) View
Infection SYSTEMATIC_ASSESSMENT Infections and infestations CTCAE (2.0) View